Processa Pharmaceuticals (PCSA) investor relations material

Executive summary

• Completed acquisition of Vidya Therapeutics, adding VT-7208, a BTK inhibitor, to the pipeline and securing $200 million in gross proceeds from a private placement, with $183.3 million in net proceeds to fund operations through 2029 and key clinical milestones.

• Settled litigation with Elion Oncology, terminating the PCS6422 program and closing the related Phase 2 trial, with a $650,000 payment and a contingent equity grant to Elion.

• Focus shifted to advancing VT-7208 in food allergy, CSU, and RMS, while continuing to evaluate legacy assets PCS499, PCS12852, and PCS11T.

Financial highlights

• Net loss for Q2 2026 was $3.3 million, compared to $3.9 million in Q2 2025; net loss for the first half of 2026 was $6.6 million, slightly lower than $6.8 million in the prior year.

• Operating expenses decreased year-over-year, mainly due to lower R&D costs as the NGC-Cap Phase 2 trial was placed on hold.

• Cash and cash equivalents dropped to $196,325 as of June 30, 2026, from $6.9 million at the end of 2025, prior to the post-period $183.3 million capital infusion.

• No revenue generated; all efforts focused on R&D and administrative support.

Outlook and guidance

• Net proceeds from the private placement are expected to fund operations into the second half of 2029 and support multiple Phase 2 studies for VT-7208.

• Anticipates increased clinical trial costs in the second half of 2026 as Phase 2 studies for VT-7208 are initiated.

• No expectation of product revenue or positive cash flow from operations in the foreseeable future.